Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Widening potential for Ca2+ antagonists: non-L-type Ca2+ channel interaction.

G Zernig1

  • 1Institut für Biochemische Pharmakologie, Innsbruck, Austria.

Trends in Pharmacological Sciences
|January 1, 1990
PubMed
Summary

Calcium (Ca2+) antagonists affect more than just L-type channels. This review explores diverse non-L-type targets, revealing commonalities that may lead to new drug development for conditions like cancer and ischemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic reference range for duloxetine in the treatment of depression revised: A systematic review and meta-analysis.

Neuroscience applied·2025
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Pharmacopsychiatry·2018
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Pharmacopsychiatry·2017
Same author

[Therapeutic drug monitoring in psychiatry. A brief summary of the new consensus paper by the task force on TDM of the AGNP].

Der Nervenarzt·2013
Same author

AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.

Pharmacopsychiatry·2011
Same author

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

Pharmacopsychiatry·2011

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cellular Physiology

Background:

  • Calcium (Ca2+) antagonists are primarily known for their interaction with the alpha 1 subunit of voltage-dependent L-type Ca2+ channels.
  • Emerging evidence indicates these antagonists also modulate diverse cellular functions beyond L-type channels, including substance extrusion and cyclic adenosine monophosphate (cAMP) cleavage.
  • Some non-canonical effects, like reversing multidrug resistance and protecting ischemic tissues, have clinical or therapeutic implications.

Purpose of the Study:

  • To survey known non-L-type Ca2+ antagonist target structures.
  • To evaluate existing data on these diverse targets.
  • To identify common characteristics among these targets and explore their therapeutic potential.

Main Methods:

Related Experiment Videos

  • Literature review and data evaluation of Ca2+ antagonist interactions with non-L-type targets.
  • Analysis of reported cellular functions modulated by Ca2+ antagonists.
  • Identification and comparison of structural or functional commonalities among diverse target sites.

    • Main Results:

    • Ca2+ antagonists interact with a growing number of cellular targets beyond the L-type Ca2+ channel.
    • These diverse targets share common characteristics, suggesting underlying unifying principles.
    • Clinical applications, such as reversing multidrug resistance, and therapeutic potentials, like protecting ischemic tissue, are highlighted.

    Conclusions:

    • Understanding non-L-type Ca2+ antagonist targets is crucial for explaining previously unexplained drug effects.
    • Identification of common features among these targets may guide the development of novel therapeutic agents.
    • Future research focusing on these non-L-type sites could lead to more selective drugs with improved therapeutic profiles.